CSL BEHRING L.L.C.

CSL Behring L.L.C. specializes in the manufacturing and supply of specialized pharmaceutical preparations, with a focused expertise in plasma-derived and recombinant biologic therapeutics. The contractor delivers critical injectable medications, including C1 esterase inhibitors like HAEGARDA, which are used to treat rare hereditary angioedema and other hematologic conditions. Their technical capabilities encompass aseptic manufacturing, cold chain logistics, regulatory-compliant production of high-purity biologics, and end-to-end pharmaceutical supply chain management under FDA and GMP standards. A key differentiator is their ability to sustain consistent, high-volume production of complex, life-sustaining biopharmaceuticals for government healthcare systems requiring stringent quality control and uninterrupted availability. The contractor maintains a consistent and long-standing relationship with the Department of Veterans Affairs, supplying essential pharmaceuticals through Federal Supply Schedule contracts and Blanket Purchase Agreements. Their work supports VA’s mission to provide specialized, chronic-care medications to veterans with rare and complex medical conditions, particularly in hematology and immunology. The recurring nature of these awards indicates a trusted, reliable vendor relationship built on consistent product quality, regulatory adherence, and timely delivery. The primary NAICS code 325412 reflects deep specialization in pharmaceutical preparation manufacturing, specifically the formulation, filling, and packaging of injectable biologics and specialty drugs. The contractor operates within the niche market of rare disease therapeutics, positioning itself as a critical supplier of high-complexity, low-volume biopharmaceuticals that require advanced manufacturing infrastructure and validated processes. CSL Behring L.L.C. is structured as a limited liability company headquartered in King of Prussia, Pennsylvania. While no government certifications are listed, the company’s consistent performance on federal pharmaceutical contracts demonstrates compliance with federal quality and regulatory frameworks. Their geographic presence supports national distribution networks, enabling reliable access to federally mandated therapeutics across VA and other federal healthcare delivery channels.